Phase II study of ACNU as first-line treatment in advanced colorectal cancer.
Thirty-two patients with metastatic colorectal cancer were entered in a phase II study of ACNU as first-line treatment. ACNU was given at a dose of 100 mg/m2 i.v. every six weeks. In 30 evaluable patients we observed partial responses lasting 5 and 8 months in 2 patients with liver metastases, and stable disease in 4 patients. The toxicity mainly consisted of leuco- and trombocytopenia. We conclude that in this dose and schedule ACNU has only very limited activity in metastatic colorectal cancer.
Planting
A
A
Department of Medical Oncology, Rotterdam Cancer Center/Dr. Daniel den Hoed Kliniek, The Netherlands.
Hoff
A
A
van der Burg
M
M
Verweij
J
J
Stoter
G
G
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D015376:Nimustine / Q000009:adverse effects / Q000627:therapeutic use*; D012983:Soft Tissue Neoplasms / Q000556:secondary
D015376:Nimustine